LOUISVILLE, CO--(Marketwire - October 28, 2008) - GlobeImmune Inc. today announced that four-week data from the on-going Phase 2 clinical trial for GI-5005, the Company's therapeutic vaccine candidate for hepatitis C, will be highlighted in the president's press conference at the 59th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in San Francisco.
